moxifloxacin has been researched along with btz 043 in 6 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (btz 043) | Trials (btz 043) | Recent Studies (post-2010) (btz 043) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 30 | 0 | 30 |
| 3,157 | 552 | 1,690 | 12 | 0 | 11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Achar, V; Ambady, A; Awasthy, D; Bathula, C; Binda, C; Chatterji, M; Chiarelli, LR; Dhar, N; Dinesh, N; Ghorpade, SR; Gorai, G; Guptha, S; Hegde, N; Hosagrahara, V; Humnabadkar, V; Iyer, PS; Jatheendranath, S; Jena, LK; Kaur, P; Kavanagh, S; Koushik, K; Madhavapeddi, P; Mahadevaswamy, J; Manjrekar, P; Manjunatha, MR; McKinney, JD; McLaughlin, B; Naik, M; Narayan, A; Narayan, C; Narayanan, S; Neres, J; Panda, M; Panduga, V; Pasca, MR; Prabhakar, K; Ramachandran, V; Ravishankar, S; Reddy, J; Riccardi, G; Rudrapatna, S; Sambandamurthy, VK; Saralaya, R; Shanbhag, G; Shandil, R; Sharma, S; Signorino-Gelo, F; Tantry, SJ; Tommasi, R; Whiteaker, J | 1 |
| Ambady, A; Butler, S; Chatterji, M; Cooper, CB; Humnabadkar, V; Iyer, PS; Jena, LK; Manjunatha, MR; McLaughlin, RE; Mdluli, K; Nanduri, R; Narayanan, S; Panda, M; Panduga, V; Prabhakar, KR; Ravishankar, S; Reddy, J; Sadler, C; Sambandamurthy, VK; Saralaya, R; Shandil, RK; Sharma, S; Shirude, PS; Srivastava, A; Suresh, RS; Whiteaker, J | 1 |
| Aguirre, DB; Augustyns, K; Balabon, O; Ballell, L; Bates, RH; Cacho, M; Casanueva, R; Cunningham, F; Guijarro, L; Huss, S; Lopez-Roman, EM; Meiler, E; Pitta, E; Rogacki, MK; Santos-Villarejo, Á; Van der Veken, P | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S | 1 |
2 review(s) available for moxifloxacin and btz 043
| Article | Year |
|---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
4 other study(ies) available for moxifloxacin and btz 043
| Article | Year |
|---|---|
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
Topics: Alcohol Oxidoreductases; Amides; Animals; Antitubercular Agents; Bacterial Proteins; Catalytic Domain; Cell Line, Tumor; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Oxidoreductases; Piperidines; Protein Binding; Quinolones; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship | 2014 |
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Cyclic Nucleotide Phosphodiesterases, Type 6; Disease Models, Animal; Humans; Indoles; Mice; Mycobacterium tuberculosis; Oxidoreductases; Rats; Structure-Activity Relationship | 2014 |
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Female; Hep G2 Cells; Humans; Hydantoins; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular; Tuberculosis | 2020 |
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Topics: | 2014 |